GLP-1 receptor

Assets acting on this target.

Class
GLP-1 receptor agonist

The glucagon-like peptide-1 (GLP-1) receptor is a G protein-coupled receptor expressed on pancreatic beta cells, in the central nervous system, and in the gastrointestinal tract. Its natural ligand, GLP-1, is an incretin hormone released from the gut after eating, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and acts on appetite-regulating centers in the brain to promote satiety. Because native GLP-1 is degraded within minutes by the enzyme dipeptidyl peptidase-4, therapeutic strategies use synthetic peptides, engineered proteins, or small molecules that activate the receptor with greater metabolic stability and prolonged duration of action. Agonism of this receptor addresses two intertwined disease processes: impaired glucose regulation in type 2 diabetes and excess body weight, since the same receptor pathway that improves insulin release and lowers blood glucose also reduces caloric intake. The breadth of chemical modalities pursued for this target, spanning injectable peptides, longer-acting fusion proteins, and increasingly oral small molecules, reflects efforts to improve convenience, dosing frequency, and manufacturing while achieving comparable receptor activation. Combination approaches pairing GLP-1 agonism with other hormonal pathways aim to extend metabolic benefit beyond what receptor activation alone provides.

By indication

Related mechanisms

GLP-1 receptor drugs compared

51 drugs, stage by indication
51 drugs acting on GLP-1 receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
dulaglutideTrulicityEli LillypeptideApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes
Liraglutide (Saxenda)SaxendaNovo NordiskpeptideApprovedApproved in Obesity
Liraglutide (Victoza)VictozaNovo NordiskpeptideApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes
lixisenatideAdlyxin / LyxumiaSanofi, Zealand PharmapeptideApprovedApproved in Type 2 Diabetes
orforglipronFoundayoChugai Pharma, Eli Lillysmall moleculeApprovedApproved in Obesity; Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Hypertension; Phase 3 in Osteoarthritis; Phase 3 in Type 2 Diabetes
Semaglutide (Ozempic)OzempicNovo NordiskpeptideApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Chronic Kidney Disease; Approved in Type 2 Diabetes
Semaglutide (Rybelsus)RybelsusNovo NordiskpeptideApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes
Semaglutide (Wegovy tablets)WegovyNovo NordiskpeptideApprovedApproved in Obesity
Semaglutide (Wegovy)WegovyNovo NordiskpeptideApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in MASH / NASH; Approved in Obesity; Phase 3 in Heart Failure with Preserved Ejection Fraction
AlbenatideConjuChem, Hebei Changshan Biochemical Pharmaceutical Co., LtdpeptidePhase 3Phase 3 in Type 2 Diabetes
aleniglipronStructure Therapeuticssmall moleculePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
ASC30Ascletis Pharmasmall moleculePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
BerobenatidePfizerpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
BofanglutideA. Menarini, Gan & Lee Pharmaceuticals, JW Pharmaceutical, Lupin LimitedpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
cagrilintide/semaglutideCagriSemaNovo NordiskpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
DA-302168SChendu DIAO Pharmaceutical Groupsmall moleculePhase 3Phase 3 in Obesity; Phase 2 in Type 2 Diabetes
ecnoglutidePfizer, Sciwind BiosciencespeptidePhase 3Phase 3 in Obesity; Phase 3 in Osteoarthritis; Phase 3 in Type 2 Diabetes
Efmedaglutide alfaShanmeiningCSPC Pharmaceutical Group, TJ Biopharma Co., Ltd.fusion proteinPhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
efpeglenatideHanmi Pharmaceutical, Laboratorios SanferpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
efsubaglutide alfaShanghai Yinnuo Pharmaceutical Technologyprotein (Fc-fusion)Phase 3Phase 3 in Type 2 Diabetes; Phase 2/3 in Obesity
elecoglipronAstraZeneca, Eccogenesmall moleculePhase 3Phase 3 in Chronic Kidney Disease; Phase 3 in Heart Failure; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
enicepatideChugai Pharma, RochepeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
exendin-4 Fc fusion (JY09)Beijing Dongfang BiotechproteinPhase 3Phase 3 in Type 2 Diabetes
HDG1901Hangzhou Zhongmei Huadong PharmaceuticalpeptidePhase 3Phase 3 in Type 2 Diabetes
HDM1002Hangzhou Zhongmei Huadong Pharmaceuticalsmall moleculePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
IcoSemaKyinsuNovo NordiskpeptidePhase 3Phase 3 in Type 2 Diabetes
MDR-001MindRank AIsmall moleculePhase 3Phase 3 in Obesity
NoiiglutideJiangsu Hengrui PharmaceuticalspeptidePhase 3Phase 3 in Type 2 Diabetes
Pegloxenatide (Fulaimei)FulaimeiHansoh Pharmaceutical GrouppeptidePhase 3Phase 3 in Type 2 Diabetes
Safiglipron (HRS-7535)Jiangsu Hengrui Pharmaceuticals, Kailera Therapeuticssmall moleculePhase 3Phase 3 in Chronic Kidney Disease; Phase 3 in Hypertension; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Heart Failure
VCT220Ji Xing Pharmaceuticals (CORXEL), Vincentage Pharmasmall moleculePhase 3Phase 3 in Obesity; Phase 2 in Hypertension; Phase 2 in Type 2 Diabetes
Visepegenatide (PB-119)PegBiopeptidePhase 3Phase 3 in Type 2 Diabetes
zovaglutideBeijing QL BiopharmaceuticalpeptidePhase 3Phase 3 in Obesity
Ecnoglutide (VRB-101)Sciwind Biosciences, Verdiva BiopeptidePhase 2Phase 2 in Obesity
Exenatide (PT320)PeptronpeptidePhase 2Phase 2 in Parkinson's Disease
regor GLP-1Regor Pharmaceuticalssmall moleculePhase 2Phase 2 in Obesity; Phase 2 in Type 2 Diabetes
SAL0150Shenzhen Salubris Pharmaceuticalssmall moleculePhase 2Phase 2 in Type 2 Diabetes
TE-8105ImmunworkpeptidePhase 2Phase 2 in Obesity
TifeglipronRochesmall moleculePhase 2Phase 2 in Obesity; Phase 2 in Type 2 Diabetes
TTP273vTv Therapeuticssmall moleculePhase 2Phase 2 in Type 2 Diabetes

Showing the 40 furthest-developed of 51 drugs. The roster below lists them all, with filters.

← all mechanisms